Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.

Judith Trotman; Christian Buske; Alessandra Tedeschi; Jeffrey V. Matous; David MacDonald; Constantine S. Tam; Olivier Tournilhac; Shuo Ma; Steven P. Treon; Albert Oriol; Jerry Ping; Eva M. Briso; Israel Arango-Hisijara; Meletios A. Dimopoulos

doi:10.1158/1078-0432.CCR-21-1497

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.

Judith Trotman
, Christian Buske
, Alessandra Tedeschi
, Jeffrey V. Matous
, David MacDonald
, Constantine S. Tam
, Olivier Tournilhac
, Shuo Ma
, Steven P. Treon
, Albert Oriol
, Jerry Ping
, Eva M. Briso
, Israel Arango-Hisijara
, Meletios A. Dimopoulos

University of Sydney
Comprehensive Cancer Center Ulm and Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany.
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Colorado Blood Cancer Institute, Denver, Colorado.
University of Ottawa
Peter MacCallum Cancer Centre
Hématologie Clinique Adulte et Thérapie Cellulaire, CHU Hotel Dieu Hématologie, Clermont-Ferrand, France.
Northwestern University
Harvard University
Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
Pharmacyclics Switzerland GmbH, an AbbVie Company, Schaffhausen, Switzerland.
National and Kapodistrian University of Athens

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Cancer Research
Volume	27
Issue number	21
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-1497
State	Published - Jan 1 2021
Externally published	Yes

Disciplines

Medicine and Health Sciences
Gastroenterology
Internal Medicine

Access to Document

10.1158/1078-0432.CCR-21-1497License: Unspecified

Cite this

Trotman, J., Buske, C., Tedeschi, A., Matous, J. V., MacDonald, D., Tam, C. S., Tournilhac, O., Ma, S., Treon, S. P., Oriol, A., Ping, J., Briso, E. M., Arango-Hisijara, I., & Dimopoulos, M. A. (2021). Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clinical Cancer Research, 27(21). https://doi.org/10.1158/1078-0432.CCR-21-1497

Trotman, J, Buske, C, Tedeschi, A, Matous, JV, MacDonald, D, Tam, CS, Tournilhac, O, Ma, S, Treon, SP, Oriol, A, Ping, J, Briso, EM, Arango-Hisijara, I & Dimopoulos, MA 2021, 'Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.', Clinical Cancer Research, vol. 27, no. 21. https://doi.org/10.1158/1078-0432.CCR-21-1497

@article{7f43b2f0f3524bfb84af563ef009fa8c,

title = "Single-Agent Ibrutinib for Rituximab-Refractory Waldenstr{\"o}m Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.",

author = "Judith Trotman and Christian Buske and Alessandra Tedeschi and Matous, \{Jeffrey V.\} and David MacDonald and Tam, \{Constantine S.\} and Olivier Tournilhac and Shuo Ma and Treon, \{Steven P.\} and Albert Oriol and Jerry Ping and Briso, \{Eva M.\} and Israel Arango-Hisijara and Dimopoulos, \{Meletios A.\}",

year = "2021",

month = jan,

day = "1",

doi = "10.1158/1078-0432.CCR-21-1497",

language = "American English",

volume = "27",

journal = "Clinical Cancer Research",

issn = "1557-3265",

publisher = "American Association for Cancer Research",

number = "21",

}

TY - JOUR

T1 - Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.

AU - Trotman, Judith

AU - Buske, Christian

AU - Tedeschi, Alessandra

AU - Matous, Jeffrey V.

AU - MacDonald, David

AU - Tam, Constantine S.

AU - Tournilhac, Olivier

AU - Ma, Shuo

AU - Treon, Steven P.

AU - Oriol, Albert

AU - Ping, Jerry

AU - Briso, Eva M.

AU - Arango-Hisijara, Israel

AU - Dimopoulos, Meletios A.

PY - 2021/1/1

Y1 - 2021/1/1

UR - https://clincancerres.aacrjournals.org/content/clincanres/early/2021/08/17/1078-0432.CCR-21-1497.full.pdf

U2 - 10.1158/1078-0432.CCR-21-1497

DO - 10.1158/1078-0432.CCR-21-1497

M3 - Article

SN - 1557-3265

VL - 27

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 21

ER -

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.

Disciplines

Access to Document

Other files and links

Cite this